Year-end Sale % OFF 
Abstract
Induced pluripotent stem cells (iPSCs) hold promise for treating recessive dystrophic epidermolysis bullosa (RDEB). An iPSC-based therapy for RDEB involves multiple steps such as reprogramming, gene correction, iPSC differentiation, and transplantation of genetically corrected iPSC-derived skin cells onto patients. Strong evidence supports the use of epidermal sheets or composite skin grafts as final therapeutic products for the transplantation of genetically corrected iPSC-derived skin cells. However, the generation of epidermal sheets or composite grafts is a lengthy and consequently expensive process.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
